Highlights
- RAD and AtomVie Global Radiopharma have partnered with Radiopharm Ventures to develop and manufacture 177Lu-BetaBart radioantibody.
- The collaboration aims to commercialise 177Lu-BetaBart, leveraging AtomVie’s manufacturing capabilities and RAD’s cutting-edge therapeutic products.
- AtomVie’s new 72,300 square foot facility, set to open in early 2025, will support the global expansion of radiotherapeutics.
Clinical-stage biopharmaceutical company Radiopharm Theranostics Limited (ASX:RAD) and AtomVie Global Radiopharma have signed a partnership agreement with Radiopharm Ventures to advance the development of 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody.
Radiopharm Ventures is a joint venture between RAD and the MD Anderson Cancer Center (MDACC). AtomVie operates as a radiopharmaceutical Contract Development and Manufacturing Organisation (CDMO), extending its services to over 25 countries worldwide.
Commenting on the development, Riccardo Canevari, Managing Director & CEO of RAD, said “Our collaboration with AtomVie is a significant step forward in our mission to bring innovative radiopharmaceutical therapies to patients. Their proven track record in manufacturing and global distribution assures us that we are in capable hands as we progress through the clinical stages and prepare for potential commercialization.”
About B7-H3
Data source: Company update
Phase I/II First-In-Human therapeutic trial with 177Lu-BetaBart in multiple tumour types in the US, is expected for mid-2025.
AtomVie to support 177Lu-BetaBart commercialisation
This collaboration combines RAD's advanced platform of radiotherapeutic products with AtomVie's manufacturing and distribution expertise. 177Lu-BetaBart is part of RAD's extensive pipeline, which includes innovative technologies in small molecules, monoclonal antibodies and peptides, sourced from leading international universities and institutes. The company expects these therapies will have significant potential to be either first-to-market or best-in-class.
AtomVie, recognised for its extensive experience in clinical development, including process and method development, technology transfer, clinical supply and international distribution, will play a crucial role in advancing 177Lu-BetaBart toward commercialisation.
AtomVie’s new 72,300 square foot state-of-the-art facility is set to open in early 2025, positioning the firm well for global expansion in radiotherapeutics.
Following this update, RAD’s share price rose by 1.89% to trade at AU$0.027 apiece at the time of writing on 16 October 2024.